16h agoStocktwits NewsBULLISH 73General
IBRX Breaks Above This Key Resistance — Stock On Track To Record Best Single-Day Gains In 6 Months
ImmunityBio stock climbed over the $10 mark for the first time since March this year.
Archived explainer. For the current picture see today's IBRX page.
Why Is IMMUNITYBIO INC (IBRX) Stock Up Today?
By the Top Tier Newswire AI Desk · October 1, 2026 at 12:08 AM ET · reviewed against 3 wire stories
IMMUNITYBIO INC (IBRX) is up +6.91% in the latest session. Our newswire has captured 3 stories on IBRX across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ImmunityBio Inc (IBRX) shares rose 6.91% to $9.44 in the session, driven by a breakout above key resistance levels and positive developments in its regulatory approvals. The stock reached a level not seen since March and is on track for its best single-day gain in six months. Recent reports highlight the stock’s performance against broader biotech declines, with IBRX bucking the trend alongside a few other names.
What Happened
ImmunityBio Inc (IBRX) shares surged past the $10 level for the first time since March, breaking above key resistance and triggering optimism among traders. The stock’s performance over the last 36 hours has been notable, with one report indicating a 12.3% rise. The move follows recent regulatory approvals in the UAE for ANKTIVA, the company’s lead drug, which received clearance for use in non-small cell lung cancer (NSCLC) after a trial showed a 14.6-month median overall survival in checkpoint-refractory patients. Additionally, the company’s Q2 financials beat estimates, with adjusted earnings per share of $(0.08) and revenue of $51.240 million, both exceeding expectations.
What The Data Shows
Over the past eight sessions, IBRX has gained 11.2%, rising from $8.85 to $9.84. The stock is currently trading within its 52-week range of $1.95 to $12.43 and has printed 27 fresh 52-week highs on September 30. Recent unusual options activity includes one notable print, with a put premium of $244K being the largest. Insiders have sold $2.7 million in shares over the past 90 days, with the most recent sale reported on July 6. The stock has a beta of 0.13 and a market cap of $9.0 billion, but remains unprofitable with a TTM EPS of -0.99.
What To Watch
The company has not scheduled earnings in the near term. Traders and investors should monitor the breadth of coverage and any further developments in regulatory approvals or clinical trial results.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IBRX by the numbers
Last: $9.44Session: +6.91%7 sessions: +11.19%Coverage: 3 stories / 2 sourcesAI sentiment: 63/100 (bullish)Mkt cap: $9.0B52w: $1.95 to $12.43
The headlines behind the move
17h agoThe FlyBULLISH 63General
ImmunityBio rises 12.3%
1d agoStocktwits NewsNEUTRAL 53General
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on IBRX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IBRX move explainers: 2026-10-01 · 2026-09-30 · 2026-08-26 · 2026-08-25 · 2026-07-11